Vascular inflammation

Journal of the American Society of Hypertension

Volumn 1, Issue 1, 2007, Pages 68-81

  Fuster, Valentin ^a   Sanz, Javier ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Atherosclerosis; biomarkers; imaging; inflammation

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACETYLSALICYLIC ACID; ALDOSTERONE ANTAGONIST; ALDOSTERONE RECEPTOR; ANGIOTENSIN RECEPTOR ANTAGONIST; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CHOLESTEROL ESTER TRANSFER PROTEIN INHIBITOR; CYTOKINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIAL NITRIC OXIDE SYNTHASE; FIBRIC ACID DERIVATIVE; FIBRINOGEN; GELATINASE B; HEAT SHOCK PROTEIN; HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; I KAPPA B; LOW DENSITY LIPOPROTEIN; MONOCYTE CHEMOTACTIC PROTEIN 1; MYELOPEROXIDASE; NITRIC OXIDE SYNTHASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PROSTAGLANDIN SYNTHASE INHIBITOR; REACTIVE OXYGEN METABOLITE; ROSUVASTATIN; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG; VASCULAR CELL ADHESION MOLECULE 1;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; BLOOD ANALYSIS; BLOOD VESSEL WALL; CARDIOVASCULAR DISEASE; CHRONIC DISEASE; COMPUTER ASSISTED TOMOGRAPHY; DIABETES MELLITUS; DIAGNOSTIC IMAGING; DIAGNOSTIC PROCEDURE; DISEASE COURSE; DISEASE SEVERITY; DRUG TARGETING; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM CELL; GENE TARGETING; HUMAN; HYPERTENSION; IN VIVO STUDY; INFLAMMATION; METABOLIC SYNDROME X; NEOVASCULARIZATION (PATHOLOGY); NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; STEM CELL; THROMBOSIS; VASCULAR DISEASE; VASCULAR ENDOTHELIUM;

EID: 34247874702     PISSN: 19331711     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jash.2006.11.005     Document Type: Article

References (106)

1. Virdis A., and Schiffrin E.L. Vascular inflammation: a role in vascular disease in hypertension?. Curr Opin Nephrol Hypertens 12 (2003) 181-187
2. Malek A.M., Alper S.L., and Izumo S. Hemodynamic shear stress and its role in atherosclerosis. JAMA 282 (1999) 2035-2042
3. Fuster V., Moreno P.R., Fayad Z.A., Corti R., and Badimon J.J. Atherothrombosis and high-risk plaque: part I: evolving concepts. J Am Coll Cardiol 46 (2005) 937-954
4. Napoli C., de Nigris F., Williams-Ignarro S., Pignalosa O., Sica V., and Ignarro L.J. Nitric oxide and atherosclerosis: an update. Nitric Oxide 15 (2006) 265-279
5. Khalil M.F., Wagner W.D., and Goldberg I.J. Molecular interactions leading to lipoprotein retention and the initiation of atherosclerosis. Arterioscler Thromb Vasc Biol 24 (2004) 2211-2218
6. Cheng C., Tempel D., van Haperen R., et al. Atherosclerotic lesion size and vulnerability are determined by patterns of fluid shear stress. Circulation 113 (2006) 2744-2753
7. Hansson G.K. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 352 (2005) 1685-1695
8. Hansson G.K. Immune mechanisms in atherosclerosis. Arterioscler Thromb Vasc Biol 21 (2001) 1876-1890
9. Bjorkbacka H., Kunjathoor V.V., Moore K.J., et al. Reduced atherosclerosis in MyD88-null mice links elevated serum cholesterol levels to activation of innate immunity signaling pathways. Nat Med 10 (2004) 416-421
10. Kiechl S., Lorenz E., Reindl M., et al. Toll-like receptor 4 polymorphisms and atherogenesis. N Engl J Med 347 (2002) 185-192
11. Gibson III F.C., Hong C., Chou H.-H., et al. Innate immune recognition of invasive bacteria accelerates atherosclerosis in apolipoprotein E-deficient mice. Circulation 109 (2004) 2801-2806
12. Tobias P., and Curtiss L.K. Thematic review series: the immune system and atherogenesis. Paying the price for pathogen protection: toll receptors in atherogenesis. J Lipid Res 46 (2005) 404-411
13. de Winther M.P., Kanters E., Kraal G., and Hofker M.H. Nuclear factor kappa-B signaling in atherogenesis. Arterioscler Thromb Vasc Biol 25 (2005) 904-914
14. Valen G., Yan Z.-Q., and Hansson G.K. Nuclear factor kappa-B and the heart. J Am Coll Cardiol 38 (2001) 307-314
15. Chinetti G., Lestavel S., Bocher V., et al. PPAR-alpha and PPAR-gamma activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway. Nat Med 7 (2001) 53-58
16. Marx N., Sukhova G.K., Collins T., Libby P., and Plutzky J. PPAR-alpha activators inhibit cytokine-induced vascular cell adhesion molecule-1 expression in human endothelial cells. Circulation 99 (1999) 3125-3131
17. Neve B.P., Corseaux D., Chinetti G., et al. PPAR-alpha agonists inhibit tissue factor expression in human monocytes and macrophages. Circulation 103 (2001) 207-212
18. Ricote M., Li A.C., Willson T.M., Kelly C.J., and Glass C.K. The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation. Nature 391 (1998) 79-82
19. Moreno P.R., Falk E., Palacios I.F., Newell J.B., Fuster V., and Fallon J.T. Macrophage infiltration in acute coronary syndromes. Implications for plaque rupture. Circulation 90 (1994) 775-778
20. Moreno P.R., Murcia A.M., Palacios I.F., et al. Coronary composition and macrophage infiltration in atherectomy specimens from patients with diabetes mellitus. Circulation 102 (2000) 2180-2184
21. Shah P.K., Falk E., Badimon J.J., et al. Human monocyte-derived macrophages induce collagen breakdown in fibrous caps of atherosclerotic plaques. Potential role of matrix-degrading metalloproteinases and implications for plaque rupture. Circulation 92 (1995) 1565-1569
22. Ivan E., Khatri J.J., Johnson C., et al. Expansive arterial remodeling is associated with increased neointimal macrophage foam cell content: the murine model of macrophage-rich carotid artery lesions. Circulation 105 (2002) 2686-2691
23. Moreno P.R., Purushothaman K.R., Fuster V., and O'Connor W.N. Intimomedial interface damage and adventitial inflammation is increased beneath disrupted atherosclerosis in the aorta: implications for plaque vulnerability. Circulation 105 (2002) 2504-2511
24. Durand E., Scoazec A., Lafont A., et al. In vivo induction of endothelial apoptosis leads to vessel thrombosis and endothelial denudation: a clue to the understanding of the mechanisms of thrombotic plaque erosion. Circulation 109 (2004) 2503-2506
25. Boyle J.J., Bowyer D.E., Weissberg P.L., and Bennett M.R. Human blood-derived macrophages induce apoptosis in human plaque-derived vascular smooth muscle cells by fas-ligand/fas interactions. Arterioscler Thromb Vasc Biol 21 (2001) 1402-1407
26. Toschi V., Gallo R., Lettino M., et al. Tissue factor modulates the thrombogenicity of human atherosclerotic plaques. Circulation 95 (1997) 594-599
27. Moreno P.R., Bernardi V.H., Lopez-Cuellar J., et al. Macrophages, smooth muscle cells, and tissue factor in unstable angina: implications for cell-mediated thrombogenicity in acute coronary syndromes. Circulation 94 (1996) 3090-3097
28. Hutter R., Valdiviezo C., Sauter B.V., et al. Caspase-3 and tissue factor expression in lipid-rich plaque macrophages: evidence for apoptosis as link between inflammation and atherothrombosis. Circulation 109 (2004) 2001-2008
29. Sambola A., Osende J., Hathcock J., et al. Role of risk factors in the modulation of tissue factor activity and blood thrombogenicity. Circulation 107 (2003) 973-977
30. Moreno P.R., Purushothaman K.-R., Sirol M., Levy A.P., and Fuster V. Neovascularization in human atherosclerosis. Circulation 113 (2006) 2245-2252
31. Moreno P.R., Purushothaman K.R., Fuster V., et al. Plaque neovascularization is increased in ruptured atherosclerotic lesions of human aorta: implications for plaque vulnerability. Circulation 110 (2004) 2032-2038
32. O'Brien K.D., McDonald T.O., Chait A., Allen M.D., and Alpers C.E. Neovascular expression of E-selectin, intercellular adhesion molecule-1, and vascular cell adhesion molecule-1 in human atherosclerosis and their relation to intimal leukocyte content. Circulation 93 (1996) 672-682
33. Kolodgie F.D., Gold H.K., Burke A.P., et al. Intraplaque hemorrhage and progression of coronary atheroma. N Engl J Med 349 (2003) 2316-2325
34. Virmani R., Kolodgie F.D., Burke A.P., et al. Atherosclerotic plaque progression and vulnerability to rupture: angiogenesis as a source of intraplaque hemorrhage. Arterioscler Thromb Vasc Biol 25 (2005) 2054-2061
35. Kristiansen M., Graversen J.H., Jacobsen C., et al. Identification of the haemoglobin scavenger receptor. Nature 409 (2001) 198-201
36. Asleh R., Marsh S., Shilkrut M., et al. Genetically determined heterogeneity in hemoglobin scavenging and susceptibility to diabetic cardiovascular disease. Circ Res 92 (2003) 1193-1200
37. Levy A.P., Hochberg I., Jablonski K., et al. Haptoglobin phenotype is an independent risk factor for cardiovascular disease in individuals with diabetes: the strong heart study. J Am Coll Cardiol 40 (2002) 1984-1990
38. Dandona P., Aljada A., Chaudhuri A., Mohanty P., and Garg R. Metabolic syndrome: a comprehensive perspective based on interactions between obesity, diabetes, and inflammation. Circulation 111 (2005) 1448-1454
39. Sjoholm A., and Nystrom T. Endothelial inflammation in insulin resistance. Lancet 365 (2005) 610-612
40. Pradhan A.D., Manson J.E., Rifai N., Buring J.E., and Ridker P.M. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 286 (2001) 327-334
41. Hilgers K.F. Monocytes/macrophages in hypertension. J Hypertens 20 (2002) 593-596
42. Diet F., Pratt R.E., Berry G.J., Momose N., Gibbons G.H., and Dzau V.J. Increased accumulation of tissue ACE in human atherosclerotic coronary artery disease. Circulation 94 (1996) 2756-2767
43. Raines E.W., and Ferri N. Thematic review series: the immune system and atherogenesis. Cytokines affecting endothelial and smooth muscle cells in vascular disease. J Lipid Res 46 (2005) 1081-1092
44. Chae C.U., Lee R.T., Rifai N., and Ridker P.M. Blood pressure and inflammation in apparently healthy men. Hypertension 38 (2001) 399-403
45. Abramson J.L., Weintraub W.S., and Vaccarino V. Association between pulse pressure and C-reactive protein among apparently healthy US adults. Hypertension 39 (2002) 197-202
46. Sesso H.D., Buring J.E., Rifai N., Blake G.J., Gaziano J.M., and Ridker P.M. C-reactive protein and the risk of developing hypertension. JAMA 290 (2003) 2945-2951
47. Smith G.D., Lawlor D.A., Harbord R., et al. Association of C-reactive protein with blood pressure and hypertension: life course confounding and Mendelian randomization tests of causality. Arterioscler Thromb Vasc Biol 25 (2005) 1051-1056
48. Wang C.-H., Li S.-H., Weisel R.D., et al. C-reactive protein upregulates angiotensin type 1 receptors in vascular smooth muscle. Circulation 107 (2003) 1783-1790
49. Verma S., Li S.-H., Badiwala M.V., et al. Endothelin antagonism and interleukin-6 inhibition attenuate the proatherogenic effects of C-reactive protein. Circulation 105 (2002) 1890-1896
50. Dzau V.J. Tissue angiotensin and pathobiology of vascular disease: a unifying hypothesis. Hypertension 37 (2001) 1047-1052
51. Schiffrin E.L. Vascular endothelin in hypertension. Vascul Pharmacol 43 (2005) 19-29
52. Cunningham K.S., and Gotlieb A.I. The role of shear stress in the pathogenesis of atherosclerosis. Lab Invest 85 (2005) 9-23
53. Tearney G.J., Yabushita H., Houser S.L., et al. Quantification of macrophage content in atherosclerotic plaques by optical coherence tomography. Circulation 107 (2003) 113-119
54. Verheye S., De Meyer G.R., Van Langenhove G., Knaapen M.W., and Kockx M.M. In vivo temperature heterogeneity of atherosclerotic plaques is determined by plaque composition. Circulation 105 (2002) 1596-1601
55. Davies J.R., Rudd J.H., Fryer T.D., et al. Identification of culprit lesions after transient ischemic attack by combined 18F-fluorodeoxyglucose positron-emission tomography and high-resolution magnetic resonance imaging. Stroke 36 (2005) 2642-2647
56. Rudd J.H., Warburton E.A., Fryer T.D., et al. Imaging atherosclerotic plaque inflammation with 18F-fluorodeoxyglucose positron-emission tomography. Circulation 105 (2002) 2708-2711
57. Weiss C.R., Arai A.E., Bui M.N., et al. Arterial wall MRI characteristics are associated with elevated serum markers of inflammation in humans. J Magn Reson Imaging 14 (2001) 698-704
58. Kooi M.E., Cappendijk V.C., Cleutjens K.B.J.M., et al. Accumulation of ultrasmall superparamagnetic particles of iron oxide in human atherosclerotic plaques can be detected by in vivo magnetic resonance imaging. Circulation 107 (2003) 2453-2458
59. Ruehm S.G., Corot C., Vogt P., Kolb S., and Debatin J.F. Magnetic resonance imaging of atherosclerotic plaque with ultrasmall superparamagnetic particles of iron oxide in hyperlipidemic rabbits. Circulation 103 (2001) 415-422
60. Choudhury R.P., Fuster V., and Fayad Z.A. Molecular, cellular, and functional imaging of atherothrombosis. Nat Rev Drug Discov 3 (2004) 913-925
61. Kelly K.A., Allport J.R., Tsourkas A., Shinde-Patil V.R., Josephson L., and Weissleder R. Detection of vascular adhesion molecule-1 expression using a novel multimodal nanoparticle. Circ Res 96 (2005) 327-336
62. Deguchi J.-o., Aikawa M., and Tung C.-H. Inflammation in atherosclerosis: visualizing matrix metalloproteinase action in macrophages in vivo. Circulation 114 (2006) 55-62
63. Takaya N., Yuan C., Chu B., et al. Presence of intraplaque hemorrhage stimulates progression of carotid atherosclerotic plaques: a high-resolution magnetic resonance imaging study. Circulation 111 (2005) 2768-2775
64. Kerwin W., Hooker A., Spilker M., et al. Quantitative magnetic resonance imaging analysis of neovasculature volume in carotid atherosclerotic plaque. Circulation 107 (2003) 851-856
65. Sirol M., Purushothaman K.R., Moreno P.R., et al. Increased neovascularization in advanced lipid-rich atherosclerotic lesions detected by gadofluorine-enhanced magnetic resonance imaging (MRI): implications for plaque vulnerability. Circulation 112 suppl-II (2005) A1184
66. Winter P.M., Morawski A.M., Caruthers S.D., et al. Molecular imaging of angiogenesis in early-stage atherosclerosis with alpha(v)beta3-integrin-targeted nanoparticles. Circulation 108 (2003) 2270-2274
67. Smith Jr. S.C., Anderson J.L., Cannon III R.O., et al. CDC/AHA workshop on markers of inflammation and cardiovascular disease: application to clinical and public health practice: report from the Clinical Practice Discussion Group. Circulation 110 (2004) e550-e553
68. Tzoulaki I., Murray G.D., Lee A.J., Rumley A., Lowe G.D., and Fowkes F.G. C-reactive protein, interleukin-6, and soluble adhesion molecules as predictors of progressive peripheral atherosclerosis in the general population: Edinburgh Artery Study. Circulation 112 (2005) 976-983
69. Zouridakis E., Avanzas P., Arroyo-Espliguero R., Fredericks S., and Kaski J.C. Markers of inflammation and rapid coronary artery disease progression in patients with stable angina pectoris. Circulation 110 (2004) 1747-1753
70. Blankenberg S., McQueen M.J., Smieja M., et al. Comparative impact of multiple biomarkers and N-terminal pro-brain natriuretic peptide in the context of conventional risk factors for the prediction of recurrent cardiovascular events in the Heart Outcomes Prevention Evaluation (HOPE) study. Circulation 114 (2006) 201-208
71. Verma S., Kuliszewski M.A., Li S.-H., et al. C-reactive protein attenuates endothelial progenitor cell survival, differentiation, and function: further evidence of a mechanistic link between C-reactive protein and cardiovascular disease. Circulation 109 (2004) 2058-2067
72. Jialal I., Devaraj S., and Singh U. C-reactive protein and the vascular endothelium: implications for plaque instability. J Am Coll Cardiol 47 (2006) 1379-1381
73. Timpson N.J., Lawlor D.A., Harbord R.M., et al. C-reactive protein and its role in metabolic syndrome: Mendelian randomization study. Lancet 366 (2005) 1954-1959
74. Koh K.K., Quon M.J., Han S.H., et al. Additive beneficial effects of fenofibrate combined with atorvastatin in the treatment of combined hyperlipidemia. J Am Coll Cardiol 45 (2005) 1649-1653
75. Esposito K., Marfella R., Ciotola M., et al. Effect of a Mediterranean-style diet on endothelial dysfunction and markers of vascular inflammation in the metabolic syndrome: a randomized trial. JAMA 292 (2004) 1440-1446
76. Esposito K., Pontillo A., Di Palo C., et al. Effect of weight loss and lifestyle changes on vascular inflammatory markers in obese women: a randomized trial. JAMA 289 (2003) 1799-1804
77. Hutter R., Carrick F.E., Valdiviezo C., et al. Vascular endothelial growth factor regulates reendothelialization and neointima formation in a mouse model of arterial injury. Circulation 110 (2004) 2430-2435
78. Walter D.H., Rittig K., Bahlmann F.H., et al. Statin therapy accelerates re-endothelialization: a novel effect involving mobilization and incorporation of bone marrow-derived endothelial progenitor cells. Circulation 105 (2002) 3017-3024
79. Rauscher F.M., Goldschmidt-Clermont P.J., Davis B.H., et al. Aging, progenitor cell exhaustion, and atherosclerosis. Circulation 108 (2003) 457-463
80. Vasa M., Fichtlscherer S., Aicher A., et al. Number and migratory activity of circulating endothelial progenitor cells inversely correlate with risk factors for coronary artery disease. Circ Res 89 (2001) E1-E7
81. Werner N., Kosiol S., Schiegl T., et al. Circulating endothelial progenitor cells and cardiovascular outcomes. N Engl J Med 353 (2005) 999-1007
82. Arnaud C., Burger F., Steffens S., et al. Statins reduce interleukin-6-induced C-reactive protein in human hepatocytes: new evidence for direct antiinflammatory effects of statins. Arterioscler Thromb Vasc Biol 25 (2005) 1231-1236
83. Laufs U., La Fata V., Plutzky J., and Liao J.K. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation 97 (1998) 1129-1135
84. Wibaut-Berlaimont V., Randi A.M., Mandryko V., Lunnon M.W., Haskard D.O., and Naoumova R.P. Atorvastatin affects leukocyte gene expression in dyslipidemia patients: in vivo regulation of hemostasis, inflammation, and apoptosis. J Thromb Haemost 3 (2005) 677-685
85. Albert M.A., Danielson E., Rifai N., Ridker P.M., and PRINCE Investigators. Effect of statin therapy on C-reactive protein l levels: the Pravastatin Inflammation/CRP Evaluation (PRINCE): a randomized trial and cohort study. JAMA 286 (2001) 64-70
86. Ridker P.M., Rifai N., Pfeffer M.A., Sacks F., Braunwald E., and The Cholesterol and Recurrent Events (CARE) Investigators. Long-term effects of pravastatin on plasma concentration of C-reactive protein. Circulation 100 (1999) 230-235
87. Ridker P.M., Cannon C.P., Morrow D., et al. C-reactive protein levels and outcomes after statin therapy. N Engl J Med 352 (2005) 20-28
88. Robinson J.G., Smith B., Maheshwari N., and Schrott H. Pleiotropic effects of statins: benefit beyond cholesterol reduction? A meta-regression analysis. J Am Coll Cardiol 46 (2005) 1855-1862
89. Corti R., Fuster V., Fayad Z.A., et al. Lipid lowering by simvastatin induces regression of human atherosclerotic lesions: two years' follow-up by high-resolution noninvasive magnetic resonance imaging. Circulation 106 (2002) 2884-2887
90. Badimon J.J., Badimon L., and Fuster V. Regression of atherosclerotic lesions by high density lipoprotein plasma fraction in the cholesterol-fed rabbit. J Clin Invest 85 (1990) 1234-1241
91. Nissen S.E., Tsunoda T., Tuzcu E.M., et al. Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA 290 (2003) 2292-2300
92. Rong J.X., Li J., Reis E.D., et al. Elevating high-density lipoprotein cholesterol in apolipoprotein E-deficient mice remodels advanced atherosclerotic lesions by decreasing macrophage and increasing smooth muscle cell content. Circulation 104 (2001) 2447-2452
93. Suc I., Escargueil-Blanc I., Troly M., Salvayre R., and Negre-Salvayre A. HDL and apoA prevent cell death of endothelial cells induced by oxidized LDL. Arterioscler Thromb Vasc Biol 17 (1997) 2158-2166
94. Nicholls S.J., Dusting G.J., Cutri B., et al. Reconstituted high-density lipoproteins inhibit the acute pro-oxidant and proinflammatory vascular changes induced by a periarterial collar in normocholesterolemic rabbits. Circulation 111 (2005) 1543-1550
95. Duffy D., and Rader D.J. Emerging therapies targeting high-density lipoprotein metabolism and reverse cholesterol transport. Circulation 113 (2006) 1140-1150
96. Zambon A., Gervois P., Pauletto P., Fruchart J.-C., and Staels B. Modulation of hepatic inflammatory risk markers of cardiovascular diseases by PPAR-alpha activators: clinical and experimental evidence. Arterioscler Thromb Vasc Biol 26 (2006) 977-986
97. Haffner S.M., Greenberg A.S., Weston W.M., Chen H., Williams K., and Freed M.I. Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation 106 (2002) 679-684
98. Pasceri V., Wu H.D., Willerson J.T., and Yeh E.T.H. Modulation of vascular inflammation in vitro and in vivo by peroxisome proliferator-activated receptor-gamma activators. Circulation 101 (2000) 235-238
99. Fliser D., Buchholz K., Haller H., and EUropean Trial on Olmesartan and Pravastatin in Inflammation and Atherosclerosis Investigators. Antiinflammatory effects of angiotensin II subtype 1 receptor blockade in hypertensive patients with microinflammation. Circulation 110 (2004) 1103-1107
100. Kuster G.M., Kotlyar E., Rude M.K., et al. Mineralocorticoid receptor inhibition ameliorates the transition to myocardial failure and decreases oxidative stress and inflammation in mice with chronic pressure overload. Circulation 111 (2005) 420-427
101. Ridker P.M., Danielson E., Rifai N., Glynn R.J., and for the Val M.I. Valsartan, blood pressure reduction, and C-reactive protein: primary report of the Val-MARC trial. Hypertension 48 (2006) 73-79
102. Schieffer B., Bunte C., Witte J., et al. Comparative effects of AT1-antagonism and angiotensin-converting enzyme inhibition on markers of inflammation and platelet aggregation in patients with coronary artery disease. J Am Coll Cardiol 44 (2004) 362-368
103. Ridker P.M., Cushman M., Stampfer M.J., Tracy R.P., and Hennekens C.H. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 336 (1997) 973-979
104. Moulton K.S., Vakili K., Zurakowski D., et al. Inhibition of plaque neovascularization reduces macrophage accumulation and progression of advanced atherosclerosis. Proc Natl Acad Sci U S A 100 (2003) 4736-4741
105. Simons M. Angiogenesis: where do we stand now?. Circulation 111 (2005) 1556-1566
106. Moreno P.R., and Fuster V. New aspects in the pathogenesis of diabetic atherothrombosis. J Am Coll Cardiol 44 (2004) 2293-2300